logo_ProQR-150x150.png
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
June 08, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces First Quarter 2020 Operating and Financial Results
May 07, 2020 07:00 ET | ProQR Therapeutics N.V.
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation...
logo_ProQR-150x150.png
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 06:00 ET | ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
logo_ProQR-150x150.png
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 16:15 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 07:00 ET | ProQR Therapeutics N.V.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
logo_ProQR-150x150.png
ProQR to Present at Cowen and Company 40th Annual Health Care Conference
February 24, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Logo.jpg
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
May 08, 2019 17:00 ET | Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Logo.jpg
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 03, 2018 17:15 ET | Celsion CORP
LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...
Logo-BCC-Research.jpg
Gene Modification Therapy Market to See 49.9% Annual Growth Through 2023
September 18, 2018 06:00 ET | BCC Research
WELLESLEY, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Recent advancements in genetic modification, including better delivery systems, more efficient and durable gene expression constructs, and...
Logo.jpg
Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations
September 17, 2018 08:30 ET | Celsion CORP
  Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives ...